Cargando…
Tenascin-C: Exploitation and collateral damage in cancer management
Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422814/ https://www.ncbi.nlm.nih.gov/pubmed/25569113 http://dx.doi.org/10.1080/19336918.2014.1000074 |
_version_ | 1782370113442283520 |
---|---|
author | Spenlé, Caroline Saupe, Falk Midwood, Kim Burckel, Hélène Noel, Georges Orend, Gertraud |
author_facet | Spenlé, Caroline Saupe, Falk Midwood, Kim Burckel, Hélène Noel, Georges Orend, Gertraud |
author_sort | Spenlé, Caroline |
collection | PubMed |
description | Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach. |
format | Online Article Text |
id | pubmed-4422814 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-44228142016-01-08 Tenascin-C: Exploitation and collateral damage in cancer management Spenlé, Caroline Saupe, Falk Midwood, Kim Burckel, Hélène Noel, Georges Orend, Gertraud Cell Adh Migr Reviews Despite an increasing knowledge about the causes of cancer, this disease is difficult to cure and still causes far too high a death rate. Based on advances in our understanding of disease pathogenesis, novel treatment concepts, including targeting the tumor microenvironment, have been developed and are being combined with established treatment regimens such as surgical removal and radiotherapy. Yet it is obvious that we need additional strategies to prevent tumor relapse and metastasis. Given its exceptional high expression in most cancers with low abundance in normal tissues, tenascin-C appears an ideal candidate for tumor treatment. Here, we will summarize the current applications of targeting tenascin-C as a treatment for different tumors, and highlight the potential of this therapeutic approach. Taylor & Francis 2015-01-08 /pmc/articles/PMC4422814/ /pubmed/25569113 http://dx.doi.org/10.1080/19336918.2014.1000074 Text en © 2015 The Author(s). Published with License by Taylor & Francis Group, LLC http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted. |
spellingShingle | Reviews Spenlé, Caroline Saupe, Falk Midwood, Kim Burckel, Hélène Noel, Georges Orend, Gertraud Tenascin-C: Exploitation and collateral damage in cancer management |
title | Tenascin-C: Exploitation and collateral damage in cancer management |
title_full | Tenascin-C: Exploitation and collateral damage in cancer management |
title_fullStr | Tenascin-C: Exploitation and collateral damage in cancer management |
title_full_unstemmed | Tenascin-C: Exploitation and collateral damage in cancer management |
title_short | Tenascin-C: Exploitation and collateral damage in cancer management |
title_sort | tenascin-c: exploitation and collateral damage in cancer management |
topic | Reviews |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4422814/ https://www.ncbi.nlm.nih.gov/pubmed/25569113 http://dx.doi.org/10.1080/19336918.2014.1000074 |
work_keys_str_mv | AT spenlecaroline tenascincexploitationandcollateraldamageincancermanagement AT saupefalk tenascincexploitationandcollateraldamageincancermanagement AT midwoodkim tenascincexploitationandcollateraldamageincancermanagement AT burckelhelene tenascincexploitationandcollateraldamageincancermanagement AT noelgeorges tenascincexploitationandcollateraldamageincancermanagement AT orendgertraud tenascincexploitationandcollateraldamageincancermanagement |